Categories
-
Wal-Mart
- General Motors
- Dow Jones
- Goldman Sachs
- Accor
- Renault
- Reuters
- BNP Paribas
- Toyota
- AgBank
- Microsoft
- Intel
- ALCATEL-LUCENT
- AXA
- Japan Airlines
- Agricultural Bank of China
- Lucien Barri
- CITIGROUP
- toutes nos catégories
Tags
Catégorie - ASTRAZENECA
17/08/09 08:27 ASTRAZENECA : L'analyse technique donne peu de signaux clairs à ...COMMUNIQUESSYNTHESE Le MACD est positif mais inférieur à sa ligne de signal. La dynamique en cours est interrompue. Dans le cas où le MACD deviendrait négatif, le repli des cours pourrait se poursuivre. Les indicateurs de puissance, comme le RSI, ne nous donnent pas d'indications particulières à court terme.
2009-08-17 - TF1
AstraZeneca relève ses prévisions après un bon 3e trimestre :LONDRES (Reuters) - AstraZeneca a relevé sa prévision de bénéfice annuel pour le deuxième trimestre d'affilée, afin de prendre en compte l'impact des ventes de son vaccin ...
2009-10-29 - Boursorama
Empirical typology of bipolar I mood episodes *... Wyeth-Ayerst Laboratories, and Merck; as consultant to Solvay Pharmaceuticals, Shire and Novartis; and on the lecture bureaux of AstraZeneca, Pfizer, ...
2009-11-30 - British Journal of Psychiatry
GIVING: Donation helps Delaware Does MoreDelaware Does More -- a statewide initiative to help needy residents with food, shelter and utilities -- got a big boost toward its fundraising goal Wednesday with a $100,000 donation from AstraZeneca.
2009-12-24 - The Daily Times
AstraZeneca to acquire French NovexelOn Wednesday, AstraZeneca announced a $350 million deal for the purchase of French antibiotics manufacturer Novexel. The acquisition will boost the Anglo-Swedish pharmaceuticals giant's portfolio of anti-infection drugs.
2009-12-24 - The Local
Movers & Shakers: Thursday's biggest gaining and declining stocksAmong the shares expected to see active trading in Thursday's session are those of the retailers as well as ABB, AstraZeneca, Bank of America, Cadbury, Immucor, Lennar, Teva.
2010-01-07 - Market Watch
London Markets: U.K. stocks post small loss; Sainsbury up on salesU.K. shares sustain a minor dip, as banking issues and Vodafone weigh on London trading just enough to eclipse gains in such names as J Sainsbury and AstraZeneca.
2010-01-07 - Market Watch
AstraZeneca prévoit des années difficilesLONDRES (Reuters) - AstraZeneca publie un bénéfice trimestriel inférieur aux attentes du marché mais s'efforce de rassurer ses actionnaires en présentant un plan de rachat d ...
2010-01-28 - Reuters France
Vague de coupes d'emplois dans les laboratoiresAprès AstraZeneca, GlaxoSmithKline annonce ce lundi un plan visant 4 000 postes. Les politiques de réajustement dans l'industrie pharmaceutique continuent de faire des vagues ...
2010-02-01 - Le Figaro
La Bourse de Londres a perdu 0,57%, plombée AstraZeneca et les ...La Bourse de Londres a reculé mercredi, pénalisée par des prises de bénéfices sur les valeurs minières, et dans un marché prudent à la veille de la décision ...
2010-02-03 - Le Point
Broker snap: Morgan Stanley keeps faith with AstraLONDON (SHARECAST) - Morgan Stanley remains a fan of the pharmaceuticals sector and has identified Swiss giant Roche and Anglo-Swedish titan AstraZeneca as its preferred picks.
2010-02-05 - ShareCast
Broker tips: Astra, Johnson Matthey, housebuildersLONDON (SHARECAST) - Morgan Stanley remains a fan of the pharmaceuticals sector and has identified Swiss giant Roche and Anglo-Swedish titan AstraZeneca as its preferred picks.
2010-02-05 - ShareCast
Dutch officials: Prevnar didn't cause deaths; AstraZeneca's fight to protect ...> The Dutch health authority RIVM said the deaths of three infants last year were not related to a vaccine produced by US pharmaceutical company Wyeth, ...
2010-02-23 - FiercePharma
Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetesBristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular ...
2010-03-10 - News-Medical-Net
Le Brilinta d'AstraZeneca réduit la mortalité après ...ATLANTA, 16 mars (Reuters) - L'anticoagulant Brilinta produit par AstraZeneca (AZN.L: Cotation ) réduit de moitié le risque de décès des patients ayant subi un pontage, si on ...
2010-03-16 - Reuters France
FDA to review Bristol-Myers/Astra diabetes drugNEW YORK - Bristol-Myers Squibb Co. and AstraZeneca said today that the Food and Drug Administration is reviewing their application for fixed dose of Onglyza in combination with metformin as a treatment for diabetes.
2010-03-17 - The Philadelphia Inquirer
ONGLYZA-metformin combination: FDA accepts NDA for reviewBristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.
2010-03-17 - News-Medical-Net
US FDA accepts NDA for once-daily fixed dose combo Onglyza & extended release Metformin for type 2 diabetes mellitus ...Bristol-Myers Squibb Company and AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.
2010-03-20 - PharmaBiz
Market Report: Astra builds on US healthcare successThe pharmaceuticals group AstraZeneca rose as the benchmark FTSE 100 index fell back last night after being hit by renewed fears of monetary tightening.
2010-03-23 - Independent
Volume gains sweeten U.S. pill for drugmakersSource: Reuters * U.S. bill short-term EPS pain, long-term sales gain * Shares of Pfizer, Bristol-Myers, AstraZeneca outperform * Sanofi-Aventis slips after setback for heart drug Multaq (Adds analyst comments ...
2010-03-22 - AlertNet
AstraZeneca, US company launch anti-diabetes drugIn an effort to grab a bite of the Rs 2,000-crore anti-diabetes market in India, UK drugmaker AstraZeneca and US pharma firm Bristol-Myers Squibb on Thursday jointly launched the oral drug Onglyza.
2010-04-01 - Express India
Abbott's combo drug hit by FDA setback(Reuters) — A experimental two-in-one heart drug from AstraZeneca and Abbott Laboratories has been knocked back by U.S. regulators who want more information about the product, the companies said on Tuesday. The move looks certain to delay approval of the drug beyond the target time of ...
2010-03-30 - Crain's Chicago Business
(AFX UK Focus) 2010-03-30 13:40 UPDATE 1-Astra, Abbott combo heart drug snagged at FDALONDON, March 30 (Reuters) - A experimental heart drug from AstraZeneca and Abbott Laboratories has been knocked back by U.S. regulators, who are seeking more information about the product. The manufacturers said on Tuesday they had received a so-called "complete response letter" from the U.S. Food and Drug Administration for Certriad, which combines Astra's blockbuster cholesterol pill Crestor ...
2010-03-30 - Interactive Investor
For $520 Million, AstraZeneca Settles Case Over Marketing of a DrugThe drug maker agreed to settle charges of improper marketing of Seroquel, an antipsychotic.
2010-04-27 - New York Times
Les grands industriels européens commencent à croire en une nette ...Pernod Ricard, Siemens, AstraZeneca et Bayer ont relevé hier leurs prévisions de profits. Dans de nombreux groupes, le début d'année se passe mieux que prévu. Un mouvement ...
2010-05-01 - Les Echos
Legality of patent deals is uncertainPatent settlements reached by drug companies including AstraZeneca may violate antitrust laws, a US appeals court has said, citing a rise in cases in which makers of brand-name medicines pay rivals to delay generic products.
2010-05-01 - The News Journal
AstraZeneca, Sanofi-Aventis post higher profitsTwo of Europe’s biggest drugmakers, AstraZeneca and Sanofi-Aventis, posted higher first-quarter profits on Thursday but diverged on optimism over performance for the rest of the year.
2010-04-29 - Market Watch
VIMOVO delayed-release tablets receive FDA approvalAstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.
2010-05-03 - News-Medical-Net
POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVOPOZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.
2010-05-26 - News-Medical-Net
London Calling: Pfizer’s Mackay to Head R&D at AstraZenecaPfizer exec Martin Mackay is decamping for cross-Atlantic rival AstraZeneca, where hell be president of R&D, a new position, Dow Jones Newswires reports . Mackay held the same title at Pfizer from 2007 to 2009, but in the wake of the companys Wyeth acquisition, he split the top job ...
2010-05-26 - Wall Street Journal Blogs
AstraZeneca Makes A Pipeline Play With Pfizer ExecMartin Mackay will become the new head of research and development at AstraZeneca.
2010-05-26 - Forbes
Malcolm Berko - ‘Blockbuster’ arthritis drug just a mix of pills now in storesOur broker, who could have been Miss America, has advised us to purchase AstraZeneca because this company has developed a new drug called Vimovo.
2010-05-28 - The Wilmington Star-News
Pozen gets $20 million milestone from AstraZeneca as a result of FDA approval ...US drug firm Pozen says it has now received a $20 million milestone payment from Anglo-Swedish drug major AstraZeneca for the US Food and Drug ...
2010-05-27 - The Pharma Letter
Asthma drug warning orderedWASHINGTON - US HEALTH regulators have finalized new warnings for controversial inhaled asthma drugs, but exercised new powers to order the changes on products made by GlaxoSmithKline Plc and AstraZeneca. The warnings, expected since February, say medicines known as long-acting beta-agonists, or LABAs, should never be used on their own to treat asthma, Food and Drug Administration officials said ...
2010-06-03 - Straits Times
AstraZeneca Buys Back 310,000 Own Shares To CancelAstraZeneca Buys Back 310,000 Own Shares To Cancel
2010-06-16 - Fox News
Pfizer joins brain-disease coalitionPfizer Inc. has joined such other major pharmaceutical firms as Abbott, AstraZeneca, Bristol-Myers, Eli Lilly & Co., Novartis and Johnson & Johnson in forming the Coalition Against Major Diseases
2010-06-15 - The Day
AstraZeneca to Pay $103 Million to Settle Drug-Pricing SuitAstraZeneca Plc, the U.K.’s second- largest drugmaker, will pay $103 million to settle claims it overcharged for some medicines in the U.S., court records show.
2010-06-19 - BusinessWeek
AstraZeneca Settles Lawsuit On Price Fixing For $103MDrug maker on Friday agreed to pay $103 million to settle lawsuits that allege it inflated the price of its cancer drug Zoladex and its child asthma medication Pulmicort.
2010-06-21 - Manufacturing.net
AstraZeneca settles U.S. pricing lawsuit for $103 mlnAstraZeneca settles U.S. pricing lawsuit for $103 mln
2010-06-18 - FOX Business
AstraZeneca Buys Back 500,000 Shares At 3041PAstraZeneca Buys Back 500,000 Shares At 3041P
2010-06-23 - Fox News
Hospira's generic antibiotic gets FDA green light(AP) — Hospira Inc. said Tuesday the Food and Drug Administration has approved its generic version of AstraZeneca's antibiotic Merrem. The FDA cleared Hospira's version of intravenous meropenem in 500-milligram and 1-gram vials. Hospira said U.S. sales of Merrem totaled $200 million in 2009.
2010-06-22 - Crain's Chicago Business
FDA approves Hospira's meropenem for injection, USP (I.V.)Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United ...
2010-06-23 - News-Medical-Net
For American Companies, a European Shopping List... the German tourism operator TUI and — for American companies with really bulging coffers — comparative corporate giants like AstraZeneca and Vivendi. ...
2010-06-23 - New York Times (blog)
ONGLYZA (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in ...Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today ...
2010-06-26 - Finanzen.net
ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In ...Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which ...
2010-06-26 - Presseportal
52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When ...Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy ...
2010-06-26 - Presseportal
La Bourse de Londres se reprend (+0,35%), emmenée par AstraZeneca ...La Bourse de Londres se reprenait modestement mercredi, après avoir dégringolé de plus de 3% la veille, emmenée par le groupe pharmaceutique AstraZeneca et ...
2010-06-30 - Le Point
Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeksBristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to ...
2010-07-02 - News-Medical-Net
AstraZeneca Teams Up With MRC Technology In Drug SearchAstraZeneca Teams Up With MRC Technology In Drug Search
2010-07-05 - FOX Business
UBS, Lewis Charles, AstraZeneca, Morgan Stanley, Isramco in Court NewsA former UBS AG client who played soccer on the Soviet national team pleaded guilty to failing to tell U.S. tax authorities about $2.6 million held in an offshore account.
2010-07-02 - Bloomberg
Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyEli Lilly & Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug lost U.S. patent protection yesterday. Lilly’s ...
2012-05-18 - Bloomberg
Plavix’s Loss Means Little Gain by Competing Blood ThinnersEli Lilly & Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug loses U.S. patent protection today. Lilly’s Effient ...
2012-05-17 - Bloomberg
AstraZeneca Antitrust Fine Should Stand, EU Court Aide SaysAstraZeneca Plc (AZN), the U.K.’s second- biggest drugmaker, shouldn’t get a further reduction for an antitrust fine of 52.5 million euros ($67.5 million), an adviser to the European Union’s highest court said. Jan Mazak, the advocate ...
2012-05-15 - Bloomberg
AstraZeneca Buys 0.6 Million Own Shares To CancelLONDON – AstraZeneca PLC (AZN.LN), said Wednesday that on May 15, it purchased for cancellation 550,000 ordinary shares of AstraZeneca PLC at a price of 2654 pence per share, adding that upon the cancellation of these shares, the number of ...
2012-05-16 - FOXBusiness
Array shares rise on lung cancer, melanoma resultsArray, which has licensed the lung cancer drug to AstraZeneca Plc, announced last year that a mid-stage trial had failed to meet its main goal of showing statistically significant improvement in overall survival. The full trial results -- released ahead of ...
2012-05-16 - msnbc.com
Amylin Said to Attract Interest From Pfizer, AstraZenecaAmylin Pharmaceuticals Inc. (AMLN) (AMLN) has lured suitors such as Pfizer Inc. (PFE) (PFE), AstraZeneca Plc (AZN) and Sanofi, which signed confidentiality agreements on the drugmaker’s sale process, said people familiar with the matter.
2012-05-14 - Businessweek
AstraZeneca implements Sales Vision CRM working on iPads!About AstraZeneca AstraZeneca plc is a British multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the worlds fifth-largest pharmaceutical company measured by 2009 prescription drug sales (after Pfizer ...
2012-05-17 - PRLog (free press release)
F-star Appoints New CEO, COO, and VP of Development and Expands Operations in Cambridge, UK BusinessJane joins from Cellzome Ltd, where she was Vice President of Business Development, and was formerly Director of Business Development at MedImmune Ltd, now part of AstraZeneca plc. Sharon has extensive experience in clinical development of biologics and small molecules.
2012-05-14 - PR Inside
AstraZeneca Buys Back 315,751 Shares/2691PAstraZeneca PLC (>> AstraZeneca plc) said Monday it bought for cancellation 315,751 of its ordinary shares at 2691 pence per share on May 11. Shares at 0750 GMT down 23 pence, or 0.87%, at 2684.5 pence valuing the company at GBP34.34 billion. -By Ian ...
2012-05-14 - 4-traders (press release)
Roche Wins U.K. NICE Backing for Tarceva in Advanced Lung CancerRoche Holding AG (ROG)’s Tarceva lung- cancer medicine won the backing of the U.K.’s health-cost agency after presenting data comparing the drug with AstraZeneca Plc (AZN)’s Iressa, which is already recommended. Tarceva is a cost-effective ...
2012-05-09 - Bloomberg